Peringatan Keamanan

There is limited information regarding acute toxicity and overdose of cemiplimab. In case of overdose, patients should be closely monitored for signs or symptoms of adverse reactions, and appropriate symptomatic treatment should be initiated.L43872

Cemiplimab

DB14707

biotech approved investigational

Deskripsi

Cemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function. By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses.L39804

Cemiplimab was first approved by the FDA on September 28, 2018, as the first FDA-approved treatment for advanced cutaneous squamous cell carcinoma (CSCC).A39201,A254177,L4615 It was later approved to be used in basal cell carcinoma and non-small non-small cell lung cancer.L39804 Cemiplimab was also approved by the European Commission on June 28, 2019.L43872 In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended cemiplimab be granted marketing authorization for the treatment of cervical cancer.L43867

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The elimination half-life (CV%) at steady state is 20.3 days (29%).[L39804]
Volume Distribusi The volume of distribution (coefficient of variation, CV%) of cemiplimab at steady-state is 5.3 L (26%).[L39804]
Klirens (Clearance) Cemiplimab clearance (CV%) after the first dose is 0.29 L/day (33%) and decreases over time by 29%, resulting in a steady-state clearance (CL<sub>ss</sub>) (CV%) of 0.2 L/day (40%).[L39804]

Absorpsi

In a pharmacokinetic study involving patients with various solid tumours, the pharmacokinetics of cemiplimab was linear and dose-proportional in the dose range of 1 mg/kg to 10 mg/kg cemiplimab administered intravenously every two weeks. When cemiplimab was administered at a dose of 350 mg every three weeks, the median steady-state concentrations (coefficient of variation, CV%) of cemiplimab ranged between 61 mg/L (45%) and 171 mg/L (28%).L39804 Steady-state exposure is achieved after four months of treatment.L39804

Metabolisme

As with other monoclonal antibodies, cemiplimab is expected to undergo nonspecific degradation into small peptides and individual amino acids.L43872

Rute Eliminasi

No information is available.

Interaksi Obat

411 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Cemiplimab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Cemiplimab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Cemiplimab.
Estrone Estrone may increase the thrombogenic activities of Cemiplimab.
Estradiol Estradiol may increase the thrombogenic activities of Cemiplimab.
Dienestrol Dienestrol may increase the thrombogenic activities of Cemiplimab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Cemiplimab.
Mestranol Mestranol may increase the thrombogenic activities of Cemiplimab.
Estriol Estriol may increase the thrombogenic activities of Cemiplimab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Cemiplimab.
Quinestrol Quinestrol may increase the thrombogenic activities of Cemiplimab.
Hexestrol Hexestrol may increase the thrombogenic activities of Cemiplimab.
Tibolone Tibolone may increase the thrombogenic activities of Cemiplimab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Cemiplimab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Cemiplimab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Cemiplimab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Cemiplimab.
Zeranol Zeranol may increase the thrombogenic activities of Cemiplimab.
Equol Equol may increase the thrombogenic activities of Cemiplimab.
Promestriene Promestriene may increase the thrombogenic activities of Cemiplimab.
Methallenestril Methallenestril may increase the thrombogenic activities of Cemiplimab.
Epimestrol Epimestrol may increase the thrombogenic activities of Cemiplimab.
Moxestrol Moxestrol may increase the thrombogenic activities of Cemiplimab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Cemiplimab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Cemiplimab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Cemiplimab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Cemiplimab.
Biochanin A Biochanin A may increase the thrombogenic activities of Cemiplimab.
Formononetin Formononetin may increase the thrombogenic activities of Cemiplimab.
Estetrol Estetrol may increase the thrombogenic activities of Cemiplimab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Cemiplimab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Cemiplimab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Cemiplimab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Cemiplimab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Cemiplimab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cemiplimab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Cemiplimab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Cemiplimab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Cemiplimab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Cemiplimab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Cemiplimab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Cemiplimab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Cemiplimab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cemiplimab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Cemiplimab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cemiplimab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Cemiplimab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Cemiplimab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cemiplimab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Cemiplimab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Cemiplimab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Cemiplimab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cemiplimab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Cemiplimab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Cemiplimab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Cemiplimab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Cemiplimab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Cemiplimab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Cemiplimab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Cemiplimab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Cemiplimab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Cemiplimab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Cemiplimab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Cemiplimab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Cemiplimab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Cemiplimab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Cemiplimab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Cemiplimab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Cemiplimab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Cemiplimab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Cemiplimab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Cemiplimab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Cemiplimab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Cemiplimab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Cemiplimab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Cemiplimab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Cemiplimab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Cemiplimab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Cemiplimab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Cemiplimab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Cemiplimab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Cemiplimab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Cemiplimab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Cemiplimab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Cemiplimab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Cemiplimab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Cemiplimab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Cemiplimab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Cemiplimab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Cemiplimab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Cemiplimab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Cemiplimab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Cemiplimab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Cemiplimab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Cemiplimab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Cemiplimab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Cemiplimab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Cemiplimab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Cemiplimab.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Cemiplimab.

Target Protein

Programmed cell death protein 1 PDCD1

Referensi & Sumber

Artikel (PubMed)
  • PMID: 29863979
    Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG: PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 Jul 26;379(4):341-351. doi: 10.1056/NEJMoa1805131. Epub 2018 Jun 4.
  • PMID: 30888929
    Jiang Y, Chen M, Nie H, Yuan Y: PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15(5):1111-1122. doi: 10.1080/21645515.2019.1571892. Epub 2019 Mar 19.
  • PMID: 24780173
    Pedoeem A, Azoulay-Alfaguter I, Strazza M, Silverman GJ, Mor A: Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol. 2014 Jul;153(1):145-52. doi: 10.1016/j.clim.2014.04.010. Epub 2014 Apr 26.
  • PMID: 28717238
    Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, Heo YS: Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep. 2017 Jul 17;7(1):5532. doi: 10.1038/s41598-017-06002-8.

Contoh Produk & Brand

Produk: 4 • International brands: 0
Produk
  • Libtayo
    Solution • 250 mg / 5 mL • Intravenous • Canada • Approved
  • Libtayo
    Solution • 350 mg / 7 mL • Intravenous • Canada • Approved
  • Libtayo
    Injection, solution, concentrate • 350 mg • Intravenous • EU • Approved
  • Libtayo
    Injection • 50 mg/1mL • Intravenous • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul